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Abstract Ubiquitination of intermediates in the interleukin-1
(IL-1) signaling cascade plays an important role in activation
and regulation of the pathway. Both IL-1 receptor associated
kinase-1 (IRAK1) and inhibitor of nuclear factor UB-K (IUBK)
are rapidly ubiquitinated and degraded. Tumor necrosis factor
associated factor-6 (TRAF6) is an ubiquitin ligase that is acti-
vated by ubiquitination and a signaling intermediate between
IRAK1 and IUBK. It is unknown whether activated TRAF6 is
subsequently degraded. We show that in liver cells IL-1 stimu-
lates TRAF6 poly-ubiquitination. In less than 1 h levels of non-
modi¢ed TRAF6 return to levels near those observed prior to
activation. TRAF6 cannot be reactivated in cells which have
been pretreated with IL-1. This observation correlates with de-
creased levels of IRAK1 in IL-1 pretreated cells. The re-estab-
lishment of non-modi¢ed TRAF6 levels following activation
does not require de novo protein synthesis, strongly suggesting
that TRAF6 is recycled via deubiquitination. This indicates a
unique mechanism of regulation of TRAF6 activity.
* 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
Tumor necrosis factor receptor associated factor-6
(TRAF6) is an essential intermediate in multiple signaling
pathways regulating such processes as bone resorption and
the innate immune response. The latter is initiated by the
recognition of pathogen by-products such as lipopolysaccha-
ride, peptidoglycan, CpG-DNA and double stranded RNA by
cellular transmembrane Toll-like receptors (TLRs) at the site
of injury/infection [1,2] which then leads to interleukin-1 (IL-
1) production. IL-1, via its receptor (IL-1R), in turn orches-
trates the systemic responses that act in concert with local
leukocytes to eliminate the pathogen (reviewed in [3]). Ligand
activation of the TLR and IL-1R leads to activation of a
common intracellular signaling cascade which initially in-
volves the recruitment of the adapter proteins MyD88 and/
or Mal/TIRAP which then recruit IL-1R associated kinase-1
(IRAK1) and IRAK4 to the intracellular domains of the
transmembrane receptors (reviewed in [4]). IRAK1 is phos-
phorylated by IRAK4 [5], an event that may lead to the dis-
sociation of IRAK1 from the membrane complex and allow
subsequent interactions with TRAF6. TRAF6 further inter-
acts with transforming growth factor L activated kinase-1
(TAK1) and the TAK1 binding proteins [4]. TAK1 in turn
activates the inhibitor of nuclear factor UB (IUB) kinase com-
plex which phosphorylates IUBK and IUBL, thereby targeting
each for ubiquitination and degradation by the proteasome.
This permits the liberated NF-UB to translocate to the nucleus
where it can initiate transcription from numerous genes im-
portant for both the innate and adaptive immune responses.
Ubiquitination, which clearly plays an important role in
regulating immune responses (reviewed in [6]), involves the
covalent attachment of several subunits of ubiquitin to a given
substrate via lysine residues. In the TLR/IL-1 signaling cas-
cade the ubiquitination and subsequent degradation of IUB is
the key event that allows NF-UB to be activated. IRAK1 is
also ubiquitinated and degraded following engagement of ei-
ther the TLR or the IL-1R [7]. However, unlike the degrada-
tion of IUB which allows activation of NF-UB, degradation of
IRAK1 is believed to provide a molecular brake on the signal-
ing cascade by limiting the availability of this factor [7^15].
It has recently been demonstrated that TRAF6 is also ubiq-
uitinated in response to IL-1 and receptor activator of NF-UB
ligand (RANKL) [16,17], and that TRAF6 is itself an ubiq-
uitin ligase that is activated by ubiquitination [18]. Although
it has been suggested that RANKL induced ubiquitination of
TRAF6 targets TRAF6 for degradation [17], the actual fate
of TRAF6 following IL-1 activation remains unknown.
Sepsis is a potentially fatal condition and is, in part, char-
acterized by a decreased ability of leukocytes to synthesize
pro-in£ammatory cytokines. Several studies have examined
the consequences of pre-exposure of monocytes/macrophages
to bacterial by-products, and have suggested that down-regu-
lation of IRAK1 levels probably plays a role in the desensiti-
zation process that may underlie the reduced activity of
monocytes/macrophages during sepsis [8^15]. Furthermore,
it has been shown that interferon-Q and granulocyte/macro-
phage colony stimulating factor can prevent desensitization
and that this may be due to stabilization of IRAK1 [12].
The liver plays an important part in the acute phase response
to infection by synthesizing agents which are essential for
eliminating pathogens, e.g. mannose binding lectin, comple-
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ment factors and the major acute phase reactants, C-reactive
protein and serum amyloid A protein [19,20]. Although the
role of the liver responses in the context of sepsis has been
poorly addressed, desensitization of the liver could also play
an important role in the pathology of septic shock.
We have investigated the fate of TRAF6 in human hepato-
ma cells (HepG2) after activation by IL-1 and here show that
TRAF6 cycles through ubiquitination and deubiquitination
before returning to its pre-activation state. We also show
that liver cells become desensitized to IL-1, i.e. TRAF6 can-
not be reactivated and IUBK is not degraded, after prior IL-1
treatment.
2. Materials and methods
2.1. Cell cultures
Human hepatoma cells (HepG2) were obtained from the American
Type Culture Collection and maintained in Dulbecco’s modi¢ed Ea-
gle’s medium (MediaTech, Herndon, VA, USA) supplemented with
10% fetal calf serum (Gemini Bio-Products, Woodland, CA, USA),
1 mM sodium pyruvate, 0.01 mM non-essential amino acids and 50
Wg/ml gentamicin (Invitrogen, Carlsbad, CA, USA). All experiments
were performed at least three times with similar outcomes.
2.2. Cytokines, antibodies and other agents
IL-1K and IL-1L were obtained from National Cancer Institute,
Frederick, MD, USA. Cells were treated with 10 ng/ml unless other-
wise stated. All antibodies were obtained from Santa Cruz Biotech-
nology (Santa Cruz, CA, USA). The following polyclonal rabbit anti-
bodies were used: anti-IUB-K (FL), anti-IRAK-1 (H-273), anti-
TRAF6 (H-274) and anti-ubiquitin (FL-76). Actinomycin D and cy-
cloheximide (Sigma, St. Louis, MO, USA) were used at 5 Wg/ml and
50 Wg/ml, respectively. The proteasome inhibitors NLVS, MG-132
and ALLN (CNbiosciences, La Jolla, CA, USA) were used at 100
WM.
2.3. Immunoprecipitation and Western blotting
Total proteins were extracted on ice in NP-40 lysis bu¡er compris-
ing 50 mM HEPES, 150 mM NaCl, 20 mM L-glycerophosphate,
1 mM EDTA, 1 mM benzamidine, 50 mM NaF, 1 mM Na3VO4,
5 mM para-nitrophenyl phosphate, 2 mM dithiothreitol, 10% protease
inhibitor cocktail (Sigma), 1% NP-40. Cellular debris was removed by
centrifugation at 10 000Ug for 10 min. Amounts of protein were
quantitated using Coomassie Protein Assay Reagent (Pierce, Rock-
ford, IL, USA) according to the manufacturer’s instructions. To pre-
clude the possibility of relocalization of TRAF6 to relatively insoluble
cellular compartments total cellular extracts were also generated in
66% lysis bu¡er, 2 M urea and 0.85% sodium dodecyl sulfate
(SDS). DNA was sheared by passing lysates through a 23G syringe
four times. No aggregates could be observed after centrifugation.
TRAF6 protein was immunoprecipitated using anti-TRAF6 and pro-
tein A agarose (Invitrogen) for 4 h at 4‡C with continuous rotation.
Immunoprecipitates were washed four times using phosphate bu¡ered
saline, 1% NP-40. Proteins were separated in NuPAGE 7% Tris-ace-
tate (TRAF6 and IRAK1) or NuPAGE 4^12% Bis-Tris (IUBK) gels
(SDS^polyacrylamide gel electrophoresis (PAGE), Invitrogen) and
transferred to Hybond ECL nitrocellulose membranes (Amersham
Pharmacia Biotech, Piscataway, NJ, USA). Proteins were detected
using speci¢c primary rabbit antibodies. Primary antibodies were rec-
ognized using horseradish peroxidase conjugated goat anti-rabbit Ig
and enhanced chemiluminescence (ECL Western blotting detection
reagents, Amersham Pharmacia Biotech). Protein bands were quanti-
tated using ImageQuaNT technology (Molecular Dynamics, Sunny-
vale, CA, USA).
3. Results and discussion
3.1. TRAF6 is ubiquitinated in response to IL-1 in HepG2 cells
Human HepG2 cells were treated with 10 ng/ml IL-1K and
total protein was harvested at various subsequent time points.
Levels of TRAF6, IRAK1 and IUBK were examined using
Western blotting. TRAF6 migrated as an approximately 60
kDa protein, in agreement with its predicted size based on
amino acid sequence. After 5 min, the intensity of the
TRAF6 band decreased to approximately 20% that observed
at the beginning of the experiment (Fig. 1A), and after 10 min
levels were further reduced to 16% of levels present prior to
treatment. At the 20 min time point levels of the 60 kDa
TRAF6 band had recovered to 72% of that observed in un-
treated cells and after 30^60 min levels had almost returned to
those observed in untreated cells (92^98%, Fig. 1A). No spe-
ci¢c bands migrating at higher molecular weight were ob-
served. For comparison IRAK1 and IUBK levels were also
examined. IRAK1 was rapidly degraded; within 5 min levels
had fallen to approximately 10% of that at 0 min and re-
mained essentially unchanged from this time point through
the end of the time course (Fig. 1B). We have recently iden-
ti¢ed an alternative splice variant of IRAK1, IRAK1b, which
is not degraded in response to IL-1 [21]. The low steady-state
Fig. 1. TRAF6 undergoes ubiquitination in response to IL-1K in
HepG2 cells. A^C: Cells were treated with IL-1K and total protein
harvested in NP-40 lysis bu¡er at the indicated time points. Equal
amounts of total protein, as determined by Coomassie assays, were
separated by SDS^PAGE, and TRAF6 (A), IRAK1 (B) and IUBK
(C) detected using Western blotting analysis with speci¢c antibodies.
Levels of protein were quantitated and are graphically represented
as percentages of those observed at the beginning of the experiment
(0 min). D: Cells were treated with IL-1K and total protein was
harvested in NP-40 lysis bu¡er at the indicated time points. TRAF6
was speci¢cally immunoprecipitated using anti-TRAF6. Washed im-
munoprecipitates were separated by SDS^PAGE and ubiquitinated
protein was detected using Western blotting analysis with anti-ubiq-
uitin. Molecular weight size markers are indicated to the left. Posi-
tions of ubiquitinated TRAF6 (Ubi-TRAF6) are indicated to the
right.
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levels of IRAK1 that persist after 5 min may represent this
splice variant. IUBK was greatly reduced (90% had disap-
peared) after 5 min (Fig. 1C) and was completely degraded
within 10 min, but reappeared at elevated levels after 30 and
60 min. A nearly two-fold increase was observed after 30 min
compared to levels at the beginning of the experiment. After
60 min levels had dropped slightly (1.4-fold increase compared
to 0 min). In cells which were treated with only 1 ng/ml IL-1K,
the results were similar except that the stages at which protein
levels changed were shifted towards later time points (not
shown), suggesting a slower processing of proteins. Similar
results were obtained using IL-1L at the same respective con-
centrations (not shown).
It has previously been shown that TRAF6 is ubiquitinated
in response to IL-1 in HeLa cells [16]. We therefore examined
whether TRAF6 is also ubiquitinated in response to IL-1 in
HepG2 cells treated with IL-1K. Total protein was harvested
at di¡erent time points following IL-1 treatment and TRAF6
was speci¢cally immunoprecipitated. Immunoprecipitated
proteins were examined using Western blotting with anti-ubiq-
uitin (Fig. 1D). High levels of ubiquitinated TRAF6 were
observed after 10 min, with somewhat lower levels persisting
at 20 min. The ubiquitinated TRAF6 migrated with apparent
molecular weights of approximately 190 and 210 kDa. Given
that the ubiquitin polypeptide is approximately 8.5 kDa, this
suggests that TRAF6 was polyubiquitinated with 15^17 ubiq-
uitin units. Although levels of non-modi¢ed TRAF6 had al-
ready declined by 5 min (Fig. 1A), no high molecular weight
ubiquitinated TRAF6 could be detected at this time point
(Fig. 1D). However, it is possible that TRAF6 at this stage
exists in many di¡erent intermediately ubiquitinated forms
containing between 1 and 14 ubiquitin subunits and that these
intermediates, which di¡er in increments of 8.5 kDa, do not
resolve as discrete bands with intensities that may readily be
detected.
The blot containing proteins immunoprecipitated with anti-
TRAF6 was reprobed with the same antibody. Again, only
the non-modi¢ed TRAF6 form was detected (not shown) cor-
relating with the result depicted in Fig. 1A. It is likely that
di¡erent antibodies from the polyclonal anti-TRAF6 mixture
are involved in recognition of native and denatured epitopes,
i.e. while some antibodies recognize native epitopes and allow
TRAF6 to be immunoprecipitated, others recognize dena-
tured epitopes in Western blotting. If ubiquitin modi¢cation
precludes recognition of the denatured (but not native) epi-
topes, immunoprecipitated ubiquitinated TRAF6 may not be
directly detectable by Western blotting with anti-TRAF6 but
may only be recognized indirectly using antibodies against
ubiquitin.
The above observations are in general agreement with pre-
viously reported [16] IL-1 induced TRAF6 ubiquitination.
However, in contrast to HeLa cells in which only a small
proportion of TRAF6 becomes ubiquitinated, and hence no
changes in levels of non-modi¢ed TRAF6 have been reported
[16], in HepG2 cells a substantial amount (approximately 84%
based on the decrease in non-modi¢ed TRAF6 levels observed
in Fig. 1A) of TRAF6 undergoes ubiquitination. Such varia-
tion in the magnitude of responses may be due to di¡erent
numbers of IL-1 receptors and/or intracellular signaling fac-
tors expressed by speci¢c cell types. Because of the more dra-
matic e¡ect upon TRAF6 modi¢cation in the HepG2 model
this system allows us to address three major questions. (1)
Can TRAF6, after pre-modi¢cation levels are re-established,
be reactivated? (2) Is ubiquitin conjugated TRAF6 eventually
degraded? (3) Is the re-constitution of non-modi¢ed TRAF6
due to de novo protein synthesis?
3.2. HepG2 cells become desensitized to IL-1 and TRAF6
cannot be reactivated
Cells were pretreated with medium only or with IL-1K for 1
or 4 h. Cells were subsequently treated with IL-1K and total
protein was harvested after 0, 10, 30 or 60 min. Levels of
TRAF6, IRAK1 and IUBK were examined using Western
blotting (Fig. 2). In cells pretreated with medium only, a tran-
sient decrease in TRAF6 levels was observed after 10 min and
levels were returning to pretreatment levels after 30^60 min.
IUBK levels were also transiently down-regulated after 10 min
and returned after 30^60 min. However, no changes in
TRAF6 or IUBK protein levels were observed in cells which
had been pretreated with IL-1K for either 1 or 4 h even
though levels of these proteins at the end of the pretreatment
period (i.e. at the time of the second IL-1K treatment) were
similar to those in cells pretreated with medium only (Fig. 2).
This suggests that the cells have become desensitized to IL-1.
In cells which were pretreated with medium only, IRAK1 was
rapidly degraded within 10 min in response to the subsequent
IL-1K treatment (Fig. 2). In cells pretreated with IL-1K
IRAK1, which was markedly down-regulated relative to the
untreated control in response to IL-1K pretreatment, re-
mained at a steady-state suppressed level, i.e. levels were not
down-regulated any further following the second IL-1K treat-
ment (Fig. 2).
Several previous studies of monocyte/macrophage desensi-
tization to bacterial by-products have suggested that the
down-regulation of IRAK1 plays an important role in the
adoption of a desensitized phenotype [8^15]. However, many
of these studies have monitored IUB degradation/NF-UB ac-
tivity and cytokine production, which are, respectively, late
Fig. 2. TRAF6 cannot be reactivated following IL-1K pretreatment. HepG2 cells were pretreated with medium only or with IL-1K for 1 h or
4 h and subsequently treated with IL-1K for 0, 10, 30 and 60 min. Total protein was harvested in NP-40 lysis bu¡er at each time point and
equal amounts of total protein, as determined by Coomassie assays, analyzed using Western blotting.
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and end-point events in the signaling cascade and hence a
consequence of successful signaling. It is therefore a possibil-
ity that one or more factors between IRAK1 and the moni-
tored end-point/consequence could also in£uence desensitiza-
tion. Our observations reported here that IRAK1 levels are
down-regulated following IL-1 treatment, and that this down-
regulation correlates with an inability to activate the immedi-
ate downstream signaling component TRAF6, further
strengthen the previous hypothesis that IRAK1 becomes a
limiting factor for the signaling cascade. The data also dem-
onstrate, to our knowledge for the ¢rst time, that liver cells
(here HepG2 cells) become desensitized to IL-1 during in£am-
mation. Such desensitization may play an important role dur-
ing sepsis since the liver is the major site of synthesis of sev-
eral circulating proteins (e.g. mannose binding lectin and
complement factors) which are directly involved in the im-
mune responses directed at eliminating pathogens [19,20].
3.3. TRAF6 is recycled via deubiquitination
Ubiquitination of IRAK1 and IUBK targets each of these
proteins for degradation. While levels of IRAK1 remain sup-
pressed for an extended period of time [8^15,21], IUBK rapidly
reappears in the cytoplasm. The latter is due to de novo NF-
UB driven gene transcription and protein synthesis (reviewed
in [22]). Although it has previously been reported that TRAF6
is ubiquitinated following IL-1 stimulation [16], it has not
been determined if TRAF6 is subsequently degraded. To ex-
amine whether inhibition of the proteasome complex would
a¡ect TRAF6 modi¢cation, cells were pretreated with me-
dium only or the proteasome inhibitors NLVS, MG-132 and
ALLN for 30 min and subsequently treated with IL-1. Total
protein lysates were harvested and levels of TRAF6 and IUBK
examined. Although degradation of IUBK was inhibited, dem-
onstrating activity of the proteasome inhibitors, no e¡ect
upon TRAF6 was observed (Fig. 3).
Since the reappearance of TRAF6 (Fig. 1A) in its non-
modi¢ed state 30 min after IL-1 treatment resembles that of
IUBK (Fig. 1C) we tested whether inhibition of de novo gene
transcription could prevent the reconstitution of non-modi¢ed
TRAF6. Cells were pretreated with medium only or actino-
mycin D for 1 h after which cells were treated with IL-1K.
Although the actinomycin D pretreatment completely abol-
ished the reappearance of IUBK, this pretreatment had no
e¡ect upon the regeneration of non-modi¢ed TRAF6
(Fig. 4). Nevertheless, it remained a possibility that TRAF6
could be reconstituted by translation from a pre-existing pool
of TRAF6 mRNA. We therefore performed a similar experi-
ment in which cells were pretreated with cycloheximide to
inhibit de novo protein synthesis. Again the reappearance of
IUBK was completely prevented (Fig. 4). However, TRAF6
reappeared after 30 min irrespective of whether cells had
been pretreated with medium only or with cycloheximide
(Fig. 4), thereby precluding the possibility that TRAF6 is syn-
thesized de novo. These observations led us to conclude that
the non-modi¢ed TRAF6 levels observed after 30^60 min of
IL-1K treatment could only be derived from the pool of
TRAF6 which was seen to be ubiquitinated at the earlier 10
and 20 min time points (Fig. 1D). Such a recycling process
would require removal of the polyubiquitin chain by deubi-
quitinating enzymes of which 90 currently are known (re-
viewed in [23]). It has previously been shown that TRAF6 is
polyubiquitinated via a unique chain formation at the lysine
residue 63 (K63) in the ubiquitin polypeptide sequence rather
than K48 [18]. It is possible that this unique polyubiquitin
chain targets TRAF6 for recycling instead of degradation.
Given that TRAF6 needs to be ubiquitinated in order to be
activated, it appears most likely that deubiquitination inacti-
vates TRAF6.
4. Conclusion
TRAF6 has recently been demonstrated to be a ubiquitin
ligase which is itself activated by ubiquitination in response to
IL-1. Several other components in the IL-1 signaling cascade
are ubiquitinated in response to IL-1 and are consequently
targeted for degradation. Here we have shown that TRAF6
distinguishes itself by being recycled via deubiquitination,
hence establishing a novel regulatory mechanism of IL-1 sig-
naling. Desensitization of liver cells may play an important
role during sepsis. We have further shown that TRAF6 can-
not be reactivated by IL-1 in cells which have been pretreated
with IL-1, and that this lack of reactivation appears to corre-
late with decreased levels of IRAK1. Further studies of the
mechanisms of desensitization of both leukocytes and hepato-
cytes may prove valuable in developing therapies against sep-
sis.
Fig. 3. TRAF6 levels are not a¡ected by the presence of proteasome
inhibitors. HepG2 cells were pretreated with medium only or with
the proteasome inhibitors NLVS, MG-132 and ALLN (Prot.Inhib.)
for 30 min and subsequently treated with IL-1K for 0 or 10 min.
Total protein was harvested in NP-40 lysis bu¡er and equal
amounts, as determined by Coomassie assays, were analyzed using
Western blotting.
Fig. 4. Non-modi¢ed TRAF6 reappears independently of de novo gene transcription or protein synthesis. HepG2 cells were pretreated with me-
dium only, actinomycin D or cycloheximide. Cells were subsequently treated with IL-1K and total protein harvested in NP-40 lysis bu¡er at
the time points indicated. Proteins were detected using Western blotting.
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